仁和药业股价下跌2.57% 上半年净利润同比减少13.87%

Core Viewpoint - Renhe Pharmaceutical's stock price has declined, reflecting challenges in revenue and profit performance in the first half of 2025 [1] Group 1: Financial Performance - As of August 26, 2025, Renhe Pharmaceutical's stock price was 6.44 yuan, down 0.17 yuan or 2.57% from the previous trading day [1] - The company reported a revenue of 1.975 billion yuan in the first half of 2025, a year-on-year decrease of 16.46% [1] - The net profit attributable to shareholders for the first half of 2025 was 290 million yuan, a decline of 13.87% compared to the same period last year [1] Group 2: Business Operations - Renhe Pharmaceutical is engaged in the research, production, and sales of traditional Chinese medicine, chemical drugs, raw materials, and health-related products [1] - The company's product range includes cold medications, gynecological drugs, and digestive system medications [1] - The company stated that there is currently no synergistic effect with Weimou Bio in the field of ophthalmic drugs and lacks information on their innovative drugs under research [1]